Top Markets
#1 Akedo Akedo +84.18%
#2 TENDIES TENDIES +73.28%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +42.58%
#5 Mubarak Mubarak +31.80%
#6 MultiversX MultiversX +27.43%
#7 Bitway Bitway +26.80%
#8 Cash Cat Cash Cat +24.01%
#9 Palladium Network Palladium Network +22.68%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Peringkat dalam Saham #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Harga Saham
$8.16
Terakhir disinkronkan: 2025-06-26
Kapitalisasi Pasar
$234.57M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Regulus Therapeutics Inc. (RGLS)

Kategori

Healthcare
Pendapatan untuk Regulus Therapeutics Inc. (RGLS)
Pendapatan pada Mar 2025 TTM: $340.00K
Menurut laporan keuangan terbaru dari Regulus Therapeutics Inc., pendapatan saat ini (TTM) adalah $340.00K. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar 0.00 sama dengan pendapatan pada tahun 2022 yang sebesar 0.00. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Regulus Therapeutics Inc. dari 2010 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) $340.00K 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 -100.00%
2020 $10.01M 46.46%
2019 $6.83M 9,388.89%
2018 $72.00K 0.00%
2017 $72.00K -93.97%
2016 $1.19M -94.25%
2015 $20.76M 170.69%
2014 $7.67M -60.81%
2013 $19.57M 54.09%
2012 $12.70M -7.90%
2011 $13.79M 60.32%
2010 $8.60M 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 3,712,929.41%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 1,770,866.86%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 655,194.12%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 4,630,584.45%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH